VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture:  MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce the results of its latest pre-clinical studies involving its Gene Expression Profiling System™ for diagnosing lymphoma.

110 RNA samples derived from human lymphoma tissues, representing the seven major subtypes of lymphoma, were analyzed utilizing a 10-fold cross-validation approach.  Using MBI’s genetic biomarkers of between 50 and 100 genes per subtype, the Gene Expression Profiling System™ achieved an average accurate prediction rate of 88% in diagnosing the various lymphoma subtypes against other lymphoma subtypes.  According to the accuracy data compiled, the median specificities for diagnosing the various subtypes averaged 97%, whereas the median sensitivities averaged 86%.

Lymphoma is a general term for a group of cancers that originate in the lymphatic system.  In Canada and the United States, lymphoma is the sixth most common cancer among males and the fifth most common cancer among females.  Approximately 56% of all blood cancers are lymphomas and approximately 73,000 Canadians and Americans will be diagnosed with lymphoma in 2007.

“We are very pleased with these results and are enthusiastic about the prospects of our Gene Expression Profiling System™ becoming a novel tool for the diagnosis of lymphoma.  In comparison to the current method of diagnosing lymphoma, we expect our Gene Expression Profiling System™ to be faster, less expensive and more accurate�, stated Erinn Broshko, Chief Executive Officer of MBI.

About Med BioGene

MBI is a biotechnology company with advanced research and development in gene expression technology.  MBI intends to utilize its expertise in gene expression to identifying those genes, known as "biomarkers," which mark the presence of various diseases.  These biomarkers will be used as an effective tool for accurate and rapid disease diagnosis and to unlock innovation in therapeutic development and treatment.  With a robust set of qualified biomarkers, disease diagnosis will be quicker, less invasive and more accurate and the safety of new therapeutics will be increased, drug products will get to patients in less time and treatment decisions will be more informed.

MBI is currently focused on developing and validating biomarkers in respect of lymphoma, leukemia and cardiovascular disease through its Gene Expression Profiling Systemâ„¢.

For further information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation.  Words such as “anticipates,� “believes,� “estimates,� “expects,� “intends,� “may,� “plans,� “projects,� “will,� “would� and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words.  Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing.  These forward-looking statements or information are only predictions based upon MBI’s current expectations, and actual events or results may differ materially.  MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information.  Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information.  You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release.  Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make.  All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.